Spirovant Sciences, a gene therapy company developing treatments for respiratory diseases, including cystic fibrosis (CF), announced today the launch of its new state-of-the-art research laboratory and corporate headquarters in Philadelphia. The new research facilities will allow the company to accelerate development of its lead program targeting CF, support the vector manufacturing process, and build capabilities to grow its platform and pipeline into therapeutic opportunities.
Castle Creek Biosciences is in late-stage development of gene therapies for rare connective tissue conditions. Its most advanced products, ex vivo therapies based on the company’s proprietary autologous fibroblast technology platform, are localized treatments administered at disease sites. New early-stage products from a recent acquisition have added in vivo, or inside the body, gene therapies, which act against the root causes of targeted diseases. The lead product, D-Fi (coded FCX-007), is now entering late-stage trials for localized treatment of skin blisters and wounds due to dystrophic epidermolysis bullosa (DEB), a rare but horrific inherited condition. Next in line is FCX-013, now in Phase 1/2, treating localized scleroderma. Other ex vivo therapies, including some to treat rare collagen disorders, are in discovery stages tightly focused on rare connective tissue conditions. In vivo gene therapies are in preclinical studies for rare metabolic and liver diseases.
SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions
SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures. The new funding brings SwanBio’s total financing raised to date to $133 million.
PIDC, Philadelphia’s public-private economic development corporation, is seeking partners to shape the next phase of growth and development on Philadelphia’s Schuylkill River with a landmark development opportunity for up to 1 MSF of state-of-the-art cell and gene therapy (CGT) manufacturing. PIDC is initiating a process that is open to responses from prospective partners – either developers or end-users – capable of planning, delivering, and managing an extraordinary campus for bioprocessing across two sites on Southwest Philadelphia’s Lower Schuylkill riverfront. PIDC seeks a developer that is committed to minority participation on the development team and that presents concepts that meet PIDC’s focus to create both 21st century manufacturing jobs and equitable inclusion strategies for the surrounding communities.
Bucks County’s Pennsylvania Biotechnology Center (PABC) generated $7.3 billion in economic activity over the past six years
The nonprofit Pennsylvania Biotechnology Center (PABC), one of the nation’s most successful life sciences incubators, generated $7.3 billion in economic activity in the region during 2016 to 2021, according to a new study commissioned by the PABC’s management.
Center for Breakthrough Medicines Beats Back on the 2022 Biotech Bear Market with Rapid Hiring and Expansion￼
Audrey Greenberg, co-founder of CBM and also the executive director of The Discovery Labs, said the successful growth seen at CBM is a testament to the great company culture the organization has built since its founding in 2019. Among the hires in the first quarter of this year is John Lee, PhD, the new Vice President and Head of Cell Therapy. Lee, an accomplished CAR-T immunobiologist, was hired in March to lead cell therapy programs at CBM. Prior to joining CBM, Lee established the Cell Therapy Platform team at Janssen Pharmaceuticals. He also served as head of Oncology Cell Therapy at GlaxoSmithKline.
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the wound site. Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain. In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours. The USAISR is the U.S. Department of Defense’s (DOD) primary laboratory for developing solutions for trauma and critical care challenges in combat casualties.
Conexus was launched in 2016, with the goal of providing outsourced commercial operations for pharmaceutical and life sciences companies. Conexus primarily focuses on the small and mid-size market, which has been somewhat ignored by other service providers, Chief Executive Officer and Founder, Akshay Kapadia told BioBuzz.
Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer
Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, has appointed Michael Klichinsky, PharmD, PhD, to the role of Chief Scientific Officer. Klichinsky co-founded the company in 2016 following his foundational work at the University of Pennsylvania that led to the development of Carisma’s chimeric antigen receptor macrophage (CAR-M) technology.
Merlin Biotech, which operates out of the Pennsylvania Biotechnology Center of Bucks County, intends to initially focus on chronic hepatitis B infections, adult and pediatric cancers, and Lyme disease.